Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00429702 · ClinicalTrials.gov registry record · Phase 2
Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy
A Phase 2 study, sponsored by University of South Florida.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00429702: Clinical Trial Phase 2 study, sponsored by University of South Florida.
NCT00429702 is a Phase 2 study that was terminated before completion, run by University of South Florida. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00429702, a Phase 2 study, was terminated before completion, sponsored by University of South Florida.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Diphenhydramine, lorazepam, and dexamethasone may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. It is not yet known whether diphenhydramine, lorazepam, and dexamethasone are more effective than standard therapy in treating nausea and vomiting caused by chemotherapy. PURPOSE: This randomized phase II trial is studying diphenhydramine, lorazepam, and dexamethasone to see how well they work compared with standard therapy in treating nausea and vomiting caused by chemotherapy in young patients with newly diagnosed cancer.
Primary Outcome
Rescue medication is any medication administered by the treating team to control breakthrough nausea or emesis. Rescue medications were used to treat any patient who has enough symptoms requiring additional therapy. All patients were instructed to first use the push button on the pump. On-demand administration of study agent via the patient-controlled infusion pump will not be considered rescue therapy - it is part of the antiemetic treatment regimen. If on-demand administration is not successfu
Interventions
- DRUG Decadron®
- DRUG Benadryl®
- DRUG Ativan®
- DRUG ondansetron hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Why NCT00429702 stopped before completion
NCT00429702 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 4 interventions - of which Decadron® is the first listed.
NCT00429702 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00429702 about?
NCT00429702 is a clinical study titled "Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy". RATIONALE: Diphenhydramine, lorazepam, and dexamethasone may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. It is not yet known whether diphenhydramine, lorazepam, and dexamethasone are more effective than standard therapy in treating nausea and vomiting caused by ...
What is the current status of trial NCT00429702?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2007-10. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00429702?
The interventions under investigation include: Decadron® (DRUG), Benadryl® (DRUG), Ativan® (DRUG), ondansetron hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00429702?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00429702's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia